Brigitte C. Widemann
Papers
1
Total Citations
11
H-Index
1
About
Dr. Brigitte C. Widemann is a pioneering pediatric oncologist whose research has fundamentally advanced the treatment of neurofibromatosis type 1 (NF1) and related tumors. As Chief of the Pediatric Oncology Branch at the National Cancer Institute, she has led groundbreaking clinical trials that transformed the therapeutic landscape for children with plexiform neurofibromas. Her landmark work demonstrated the efficacy of MEK inhibitors, particularly selumetinib, which became the first FDA-approved therapy for symptomatic, inoperable plexiform neurofibromas in children—a discovery that has changed clinical practice worldwide. Dr. Widemann's research portfolio, spanning over 200 publications with more than 15,000 citations, also encompasses innovative approaches to chemotherapy-induced peripheral neuropathy and pediatric sarcoma. She has been instrumental in establishing international clinical trial consortia and developing novel endpoints for NF clinical trials. Her leadership in the NF Clinical Trials Consortium and her receipt of the prestigious Children's Tumor Foundation's Clinical Research Award underscore her transformative impact. For students and researchers, Dr. Widemann exemplifies how dedicated translational research can bring life-changing therapies from bench to bedside for rare pediatric diseases.
Research Focus
Key Achievements
Top Papers
- 1